Originally published as JCO Early Release 10.1200/JCO.2004.10.020 on September 27 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Witzig, T. E. Articles by Morton, R. F. Search for Related Content PubMed PubMed Citation Articles by Witzig, T. E. Articles by Morton, R. F. Related Articles Related Article

Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy

From the Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN

Address reprint requests to Thomas E. Witzig, MD, Mayo Clinic, Stabile 6-28, 200 First St SW, Rochester, MN 55905; e-mail: witzig{at}mayo.edu

PURPOSE: To determine whether weekly epoetin alfa could improve hemoglobin (HgB) levels, reduce RBC transfusions, and improve quality of life (QOL) in patients with advanced cancer and with anemia after receiving myelosuppressive chemotherapy.

PATIENTS AND METHODS: This double-blind, placebo-controlled study randomly assigned patients to placebo or epoetin alfa (Ortho Biotech, Bridgewater, NJ) 40,000 U subcutaneous weekly for 16 weeks. QOL, HgB, and RBC transfusions were measured pretreatment and monthly.

RESULTS: The study accrued 344 patients; 330 were assessable for efficacy and 305 were assessable for QOL. Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, –3.8 to +5.3) compared with 2.8 g/dL (range, –2.2 to +7.5) for epoetin-treated patients (P < .0001). During the study, 31.7% of placebo-treated patients achieved a 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001). The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively. The placebo group received 256 units of RBCs compared with 127 units in the epoetin group (P < .0001). The incidence of toxicity in the groups was similar. Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant). The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with –2.1 for the nonresponders (P = .006).

CONCLUSION: Epoetin alfa significantly improved HgB and reduced transfusions in this patient population. These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Article

• Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials
  George P. Browman
  JCO 2005 23: 2583-2585 [Full Text]

This article has been cited by other articles:

				P. Gascon Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications Oncologist, May 1, 2008; 13(suppl_3): 4 - 10. [Abstract] [Full Text] [PDF]

				M. Dicato Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update Oncologist, May 1, 2008; 13(suppl_3): 11 - 15. [Abstract] [Full Text] [PDF]

				J.-P. Spano and D. Khayat Treatment Options for Anemia, Taking Risks into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions Oncologist, May 1, 2008; 13(suppl_3): 27 - 32. [Abstract] [Full Text] [PDF]

				M. S. Aapro and H. Link September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents Oncologist, May 1, 2008; 13(suppl_3): 33 - 36. [Abstract] [Full Text] [PDF]

				Y. Suzuki, Y. Tokuda, Y. Fujiwara, H. Minami, Y. Ohashi, and N. Saijo Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 214 - 221. [Abstract] [Full Text] [PDF]

				C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia JAMA, February 27, 2008; 299(8): 914 - 924. [Abstract] [Full Text] [PDF]

				J. A. Sloan, L. Berk, J. Roscoe, M. J. Fisch, E. G. Shaw, G. Wyatt, G. R. Morrow, and A. C. Dueck Integrating Patient-Reported Outcomes Into Cancer Symptom Management Clinical Trials Supported by the National Cancer Institute Sponsored Clinical Trials Networks J. Clin. Oncol., November 10, 2007; 25(32): 5070 - 5077. [Abstract] [Full Text] [PDF]

				T. R. Lappin, A. P. Maxwell, and P. G. Johnston Warning Flags for Erythropoiesis-Stimulating Agents and Cancer-Associated Anemia Oncologist, April 1, 2007; 12(4): 362 - 365. [Full Text] [PDF]

				J. R. Wright, Y. C. Ung, J. A. Julian, K. I. Pritchard, T. J. Whelan, C. Smith, B. Szechtman, W. Roa, L. Mulroy, L. Rudinskas, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non-Small-Cell Lung Cancer With Disease-Related Anemia J. Clin. Oncol., March 20, 2007; 25(9): 1027 - 1032. [Abstract] [Full Text] [PDF]

				Y. Morishima, M. Ogura, S. Yoneda, H. Sakai, K. Tobinai, Y. Nishiwaki, H. Minami, T. Hotta, K. Ezaki, Y. Ohe, et al. Once-Weekly Epoetin-Beta Improves Hemoglobin Levels in Cancer Patients with Chemotherapy-Induced Anemia: A Randomized, Double-Blind, Dose-Finding Study Jpn. J. Clin. Oncol., October 1, 2006; 36(10): 655 - 661. [Abstract] [Full Text] [PDF]

				B. I. Razzouk, J. D. Hord, M. Hockenberry, P. S. Hinds, J. Feusner, D. Williams, and W. R. Rackoff Double-Blind, Placebo-Controlled Study of Quality of Life, Hematologic End Points, and Safety of Weekly Epoetin Alfa in Children With Cancer Receiving Myelosuppressive Chemotherapy J. Clin. Oncol., August 1, 2006; 24(22): 3583 - 3589. [Abstract] [Full Text] [PDF]

				D. P. Steensma and C. L. Loprinzi Epoetin Alfa and Darbepoetin Alfa Go Head to Head J. Clin. Oncol., May 20, 2006; 24(15): 2233 - 2236. [Full Text] [PDF]

				J. Glaspy, S. Vadhan-Raj, R. Patel, L. Bosserman, E. Hu, R. E. Lloyd, R. V. Boccia, D. Tomita, and G. Rossi Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial J. Clin. Oncol., May 20, 2006; 24(15): 2290 - 2297. [Abstract] [Full Text] [PDF]

				J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714. [Abstract] [Full Text] [PDF]

				D. P. Steensma, R. Molina, J. A. Sloan, D. A. Nikcevich, P. L. Schaefer, K. M. Rowland Jr, T. Dentchev, P. J. Novotny, L. K. Tschetter, S. R. Alberts, et al. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1079 - 1089. [Abstract] [Full Text] [PDF]

				J.-L. Canon, J. Vansteenkiste, G. Bodoky, M. V. Mateos, L. Bastit, I. Ferreira, G. Rossi, and R. G. Amado Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, February 15, 2006; 98(4): 273 - 284. [Abstract] [Full Text] [PDF]

				K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355. [Abstract] [Full Text] [PDF]

				J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared with Population Normative Data. Oncologist, February 1, 2006; 11(2): 197 - 205. [Abstract] [Full Text] [PDF]

				J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist, February 1, 2006; 11(2): 206 - 216. [Abstract] [Full Text] [PDF]

				B. Coiffier Response to "Effect of Patient Exclusion Criteria on the Efficacy of Erythropoiesis-Stimulating Agents in Patients with Cancer-Related Anemia" Oncologist, October 1, 2005; 10(9): 762 - 763. [Full Text] [PDF]

				R. Waltzman, C. Croot, G. R. Justice, M. R. Fesen, V. Charu, and D. Williams Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 {micro}g Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, September 1, 2005; 10(8): 642 - 650. [Abstract] [Full Text] [PDF]

				R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]

				G. P. Browman Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials J. Clin. Oncol., April 20, 2005; 23(12): 2583 - 2585. [Full Text] [PDF]